Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 IV eptinezumab in chronic migraine
2016-001306-41Phase 3Completed
- Sponsor
- Alder Biopharmaceuticals
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine and migraine comparing Eptinezumab IV with Placebo IV (2 arms). Primary endpoint: Change in frequency of migraine days. Started Dec 2016; status: completed.
02
Drugs
eptinezumab
03
Conditions
chronic migrainemigraine
Beyond the preview
Go deeper on 2016-001306-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001306-41.